spacer
home > ebr > summer 2017 > cut and paste
PUBLICATIONS
European Biopharmaceutical Review

Cut and Paste

The successful sequencing of the human genome in 2003 was a momentous accomplishment and has turned out to be a gift that keeps on giving. A renewed understanding of biology and pathophysiology has advanced the knowledge and utility of many existing fields, such as rare diseases, genetic disorders and cancer, to name but three. As a result, there has been an explosion of new techniques to diagnose, prevent and treat pathologies. This singular event has also led to the spawning of new areas like next-generation sequencing and gene-editing. The latter is a disruptive emerging technology that has the potential to alter the way we view genetic or gene-related diseases, changing many from being lethal to chronic at worst and curable at best.

CRISPR-Cas9


Heraclitus, a Greek philosopher, is credited with saying that ‘change is the only constant in life’; in science, this continues to prove true. In the 90s, gene therapy was hailed as the next big thing at the cutting edge of science. Revolutionary as it was, it has stuttered and spluttered, failing to break into the realms of mainstream therapies. Gene therapy involves using a neutered virus (known as a viral vector) to deliver a synthetic functioning copy of a gene into cells. The trouble is that there is no control over where the gene will end up in the three billion DNA base pairs, hence it is a rather blunt instrument.

While gene therapies were still experiencing teething problems, two bacteriologists serendipitously discovered a process that would progress genetic science. They observed that bacteria, when defending themselves from a virus, would replicate the virus’s DNA and attach a key enzyme called Cas9. This would then unlock the DNA of the virus, break and disable it, thereby rendering the virus impotent. Mimicking this clever process from nature, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology was born.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jimmy Muchechetere is a Healthcare and Biotech Research Analyst at Investec, having joined the financial industry in 2011 at Williams De Broë (now Investec Wealth & Investment) as a Research Intern. He is responsible for the equity research of all pharma as well as other healthcare and biotech companies across the globe. Jimmy also oversees the smooth running of the research department’s international service and is a registered medical doctor with seven years’ experience.
spacer
Jimmy Muchechetere
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

BIO-Europe® 2019 - 25th Annual International Partnering Conference

11-13 November 2019, Hamburg, Germany

The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Learn more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement